60
Participants
Start Date
February 24, 2025
Primary Completion Date
July 1, 2029
Study Completion Date
July 1, 2029
68Ga-PSMA-PET/CT scan
68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure
RECRUITING
NKI-AVL, Amsterdam
RECRUITING
Meander Medisch Centrum, Amersfoort
RECRUITING
Sint Antonius ziekenhuis, Nieuwegein
NOT_YET_RECRUITING
Diakonessenhuis, Utrecht
RECRUITING
UMC, Utrecht
Collaborators (1)
Bayer
INDUSTRY
The Netherlands Cancer Institute
OTHER